A TOR-targeting cancer drug unexpectedly extends yeast lifespan through a newly discovered metabolic feedback loop. Researchers at Queen Mary University of London’s School of Biological and Behavioural Sciences have found that the new TOR inhibitor rapalink-1 can extend the chronological lifespan of simple fission yeast, which they used as a model organism. The study, published […]
Source link